Resources

Publications, application notes and more

  • Blog14 August 2019

    Getting to the heart of the matter: GPCRs as therapeutic targets for heart failure

    In this blog post we cover the functions of key GPCRs in the heart and how they are now being targeted for therapeutic treatments to reduce the impact of coronary heart disease

  • Publication01 August 2019

    Analysis of αB-crystallin polydispersity in solution through native microfluidic electrophoresis

    In this paper, the authors utilise microfluidic diffusional sizing and electrophoresis to characterise the oligomeric states of the chaperone protein alphaB-crystallin.

  • Publication25 July 2019

    Gradient-free determination of isoelectric points of proteins on chip

    Lapinska et al. using a microfluidic system built in house design a new technique to determine a protein's isoelectric point (pI) based on microfluidic free-flow electrophoresis (μFFE). The approach exploits temporal rather than spatial pH gradients. To demonstrate the effectiveness of this method the pI of 7 different proteins of known pI were tested; β-lactoglobulin, ribonuclease A, ovalbumin, human transferrin, ubiquitin and myoglobin. The paper shows that this method is successful in determining the pI using this new technique without the requirement of generating and maintaining pH gradients which is often challenging for other techniques. The technique requires low voltages and low sample consumption. The paper also shows that using this technique it is possible to estimate the pI values for a wide range of proteins measuring at only two pH values, suggesting that this technique is rapid and accurate on small volume samples.

  • Blog11 July 2019

    Understanding why GPCRs are difficult to study

    In this blog post we delve into the reasons behind why elucidating GPCR structures are so important as well as why they are hard to study.

  • Infographic11 July 2019

    Researching therapies for Alzheimer’s Disease

    In this infographic, we break down all the failures of potential therapies that were tested to treat Alzheimer's Disease. This includes a cost and percentage breakdown of the clinical phases in which these therapies failed in as well as statistics for world-wide Alzherimer's Disease epidemiology.

  • Publication04 June 2019

    Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates

    In this paper MDS was used to identify two molecular chaperones which suppress secondary nucleation processes and inhibit the elongation of Aβ fibrils seen in Alzheimer's disease.

  • Blog17 July 2018

    What biophysical attributes of biopharmaceuticals are measured, and why?

    An array of characteristics must be investigated in new biopharmaceuticals to evaluate their safety, efficacy and behaviour under changing conditions. Here we look at what specific attributes should be measured and why.